Sales of TNF-a inhibitor for rheumatoid arthritis increased by 21% compared to the previous year
On September 4, according to the sales analysis of recently released TNF-a inhibitor and new drug for rheumatoid arthritis treatment in the second half of the year, its sales increased by 21% compared to the previous year.
The growth was driven by Humira (Abbvie) and Remicade (Janssen) which rec...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
